BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35196866)

  • 1. Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.
    Russell-Smith TA; Gurskyte L; Muresan B; Mamolo CM; Gezin A; Cappelleri JC; Heeg B
    Future Oncol; 2022 May; 18(16):2029-2039. PubMed ID: 35196866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel Strategies to Treat Acute Myeloid Leukemia].
    Gediga MHE; Middeke JM; Ruhnke L
    Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.
    Açar İH; Guvenc B
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984499
    [No Abstract]   [Full Text] [Related]  

  • 6. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
    Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature.
    Blain S; Payette N; Bittencourt H; Johnston DL
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):436-444. PubMed ID: 37807192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of gilteritinib (Xospata
    Mori M; Hidaka K
    Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
    Sumiyoshi R; Tashiro H; Saito S; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2020 Aug; 99(35):e22064. PubMed ID: 32871966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
    Tang K; Schuh AC; Yee KW
    Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
    Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
    Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
    Genthon A; Brissot E; Malard F; van de Wyngaert Z; Bonnin A; Banet A; Marjanovic Z; Ikhlef S; Lapusan S; Sestili S; Corre E; Paviglianiti A; Adaeva R; 'Hammedi-Bouzina FM; Labopin M; Dulery R; Mohty M; Legrand O
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):791-796. PubMed ID: 32741743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
    Debureaux PE; Labopin M; Mamez AC; Lapusan S; Isnard F; Adaeva R; Bonnin A; Hirsch P; Delhommeau F; Battipaglia G; Duléry R; Malard F; Vekhoff A; Mohty M; Legrand O; Brissot E
    Bone Marrow Transplant; 2020 Feb; 55(2):452-460. PubMed ID: 31554931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin for
    Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
    Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.